CPT (circularly permuted TRAIL) is a recombinant human mutant of Apo2L/TRAIL developed by Beijing Sunbio Biotech, Co. Ltd. in China, and was tested in relapsed and refractory multiple myeloma as a single agent [115,116], or in combination with thalidomide (T), or in combination with thalidomide and dexamethasone (TD) [117,118]. The gene discussed is TNFSF10; the disease is AL amyloidosis.